ClinicalTrials.gg
RecruitingNCT05668598ECOTESTGERUpdated May 8, 2026

Creation of an Ecological Tool Assessing Episodic Memory in Geriatrics

An interventional study of ecological MAI test in Memory Disorders and Neurocognitive Disorders, sponsored by Centre Hospitalier de Lens. Recruiting at 1 site in France. Open to participants aged 70 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Centre Hospitalier de Lens · Not applicable, Interventional, and Other

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
70 Years and older
Sex
All
01

Study summary

In this study the participants can be recruited via scheduled consultation and external institutions (associations, senior club..). Neuropsychological assessment will be realize to determine presence or absence of neurodegenerative disease.

Study test is ecological MAI. This test are assigned in two groups (with or without neurocognitive disorders).

Read the detailed description

In this study the participants can be recruited via scheduled consultation and external institutions (associations, senior club..). Neuropsychological assessment will be realize to determine presence or absence of neurodegenerative disease.

Study test is ecological MAI. Participation will be 30 minutes for patients see in case of routine care and 2h30 for those accompanying the patients and participants recruited in external institutions.

Participants are assigned in two groups. Group 1 : with neurocognitive disorders Group 2 : without neurocognitive disorders

Benefits :

For participants without neurodegenerative disorder, study enables to take control early if anomaly will be detected.

The study permit to have cognitive assessment.

Risk : It's possible that participants feel tired. No constraints for participants seen during scheduled consultation.

02

Conditions studied

  • Memory Disorders
  • Neurocognitive Disorders

Keywords

  • GERIATRICS
03

In context

Memory Disorders

373 studies on the registry are indexed under Memory Disorders; 67 are open to participants now.

This study's planned enrollment of 60 is below the median of 72 across 298 interventional studies indexed under Memory Disorders.

Browse Memory Disorders studies →

Lead sponsor

Centre Hospitalier de Lens is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ≥ 70 ans
  • Person have good locomotion, move independently
  • Personne agree to participate

Groupe 1 : 17≤≤24 (GRECO) Diagnosis of neurodegenerative diseases (major neurocognitive disorders: Alzheimer, mixed dementia, lobar frontotemporal degeneration, vascular dementia).

Groupe 2 : MMSE ≥ à 25 (GRECO) Without neurodegenerative disease

Exclusion criteria

Exclusion Criteria:

  • Person with legal protective measures
  • Person deprived of liberty
  • Mental retardation or ≤ 16
  • Understanding verbal disorders
  • Visual major disturbances
  • Person with disease causing increased fatigue
  • Person with psychiatric pathology excepted anxiety disorder or depression with mild episodes.
  • Person not covered by French national health insurance
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Other
    Groupe 1 : with neurocognitive disorders

    with neurocognitive disorders

    Diagnostic Test: ecological MAI test

  • Other
    Groupe 2 : without neurocognitive disorders

    without neurocognitive disorders

    Diagnostic Test: ecological MAI test

Interventions

  • Diagnostic testecological MAI test

    Neuropsychological assessment will be realize to determine presence or absence of neurodegenerative disease. Study test is ecological MAI.

06

What researchers measure

Primary outcomes

  1. To compare performance obtaining to overall score remind ecological MAI between older persons with neurocognitive disorders (groupe 1) and older persons without neurocognitive disorders (groupe 2).

    Overall score remind ecological MAI test (0 to 12) in two groups.

    Time frame: day 1

Secondary outcomes

  1. To compare between case and control the various dimensions of episodic memory: temporal component, space component and association component.

    Spatial component is defined by localisation score. Score (0 to 12)

    Time frame: day 1

  2. To compare between case and control the various dimensions of episodic memory: temporal component, space component and association component.

    Temporal component is defined by temporal dimension. Score (0 to 12)

    Time frame: day 1

  3. To compare between case and control the various dimensions of episodic memory: temporal component, space component and association component.

    Association component is defined by binding score. Score (0 to 12)

    Time frame: day 1

07

Study locations

1 of 1 sites recruiting
  • Centre Hospiralier de Lens
    Lens, 62408, France
    Recruiting
    • MELANIE VERLAY · Contactmverlay@ch-lens.fr · 0601023068
    • BRUNHILDE CANESSON · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05668598
Lead sponsor
Centre Hospitalier de Lens
Responsible party
Sponsor
First posted
Dec 30, 2022
Start date
Mar 8, 2023
Primary completion
Mar 8, 2028 (estimated)
Completion
Mar 9, 2028 (estimated)
Last update
May 8, 2026

Study contacts

Brunhilde CANESSON
Contact
bcanesson@ch-lens.fr
03.21.69.16.36 ext. +33
Mélanie VERLAY
Contact
mverlay@ch-lens.fr
03.21.69.10.28 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion